|
|
|
|
|
Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis |
| JIN Tongtong1, ZHOU Chuan1, WANG Chao1, DA Zijian1, ZHOU Fenghai1,2 |
| 1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China; 2. Department of Urology, Gansu Provincial People’s Hospital, Lanzhou 730000, China |
|
|
|
|
Abstract Objective To visualize and analyze the literature related to immunotherapy for prostate cancer published in the past 20 years through bibliometric analysis, and to explore the research progress and cuttingedge trends in this field. Methods The Web of Science core collection database was searched for literature related to immunotherapy for prostate cancer published from 2002 to 2021. CiteSpace and VOSviewer software were used to visualize and analyze the data and map the evolution of hotspots. Results There were 2 326 papers were finally included after excluding irrelevant studies. The field of immunotherapy for prostate cancer is in a rapid development stage; the United States has a great influence and China has a significant latecomer advantage; the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and University of California, San Francisco are the main research institutions; American authors Gulley JL, Schlom J and Japanese author Itoh K have the highest number of publications. Currently, the main research hotspot is immune checkpoint inhibitors, and high-quality clinical trials are continuing to drive this process forward. Conclusion The exploration of novel immune pathways and the combination of different therapies will be the main trend of future research in immunotherapy for prostate cancer.
|
| Keywords
Prostatic neoplasms
Immunotherapy
Immune checkpoint inhibitors
Bibliometrics
Visualization analysis
|
|
|
| Fund:Gansu Provincial Science and Technology Program (Key R&D Program) (No. 21YF5FA016) |
|
Issue Date: 14 July 2022
|
|
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,
71(3): 209-249.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,
2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer[J]. Onco Targets Ther, 2016, 9: 7263-7274.
[4] Xavier-Santos D, Padilha M, Fabiano GA, et al. Evidences and
perspectives of the use of probiotics, prebiotics, synbiotics,
and postbiotics as adjuvants for prevention and treatment of
COVID-19: A bibliometric analysis and systematic review[J].
Trends Food Sci Technol, 2022, 120: 174-192.
[5] Wu M, Wang Y, Yan C, et al. Study on subclinical hypothyroidism
in pregnancy: a bibliometric analysis via CiteSpace[J]. J Matern
Fetal Neonatal Med, 2022, 35(3): 556-567.
[6] Cheng P, Tang H, Dong Y, et al. Knowledge Mapping of Research
on Land Use Change and Food Security: A Visual Analysis Using
CiteSpace and VOSviewer[J]. Int J Environ Res Public Health,
2021, 18(24): 13065.
[7] 陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J].
科学学研究, 2015, 33(2): 242-253. [Chen Y, Chen CM, Liu ZY,
et al. The methodology function of CiteSpace mapping knowledge
domains[J]. Ke Xue Xue Yan Jiu, 2015, 33(2): 242-253.]
[8] Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of
PD-1 and PD-L1 inhibitor-based combination therapies in clinical
trials: a systematic review and meta-analysis[J]. Lancet Oncol,
2021, 22(9): 1265-1274.
[9] Kennedy LB, Salama AKS. A review of cancer immunotherapy
toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104.
[10] Gulley JL, Borre M, Vogelzang NJ, et al. Phase Ⅲ Trial of
PROSTVAC in Asymptomatic or Minimally Symptomatic
Metastatic Castration-Resistant Prostate Cancer[J]. J Clin Oncol,
2019, 37(13): 1051-1061.
[11] Noguchi M, Arai G, Egawa S, et al. Mixed 20-peptide cancer
vaccine in combination with docetaxel and dexamethasone for
castration-resistant prostate cancer: a randomized phase Ⅱ trial[J].
Cancer Immunol Immunother, 2020, 69(5): 847-857.
[12] Bilusic M, McMahon S, Madan RA, et al. Phase Ⅰ study of a
multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based
immunotherapy vaccine in patients with metastatic castrationresistant
prostate cancer (mCRPC)[J]. J Immunother Cancer,
2021, 9(3): e002374.
[13] Sartor O, Armstrong AJ, Ahaghotu C, et al. Survival of African-
American and Caucasian men after sipuleucel-T immunotherapy:
outcomes from the PROCEED registry[J]. Prostate Cancer
Prostatic Dis, 2020, 23(3): 517-526.
[14] Sonpavde G, Di Lorenzo G, Higano CS, et al. The role of
sipuleucel-T in therapy for castration-resistant prostate cancer: a
critical analysis of the literature[J]. Eur Urol, 2012, 61(4): 639-647.
[15] Crawford ED, Petrylak DP, Higano CS, et al. Optimal timing of
sipuleucel-T treatment in metastatic castration-resistant prostate
cancer[J]. Can J Urol, 2015, 22(6): 8048-8055.
[16] Seitter SJ, Sherry RM, Yang JC, et al. Impact of Prior Treatment
on the Efficacy of Adoptive Transfer of Tumor-Infiltrating
Lymphocytes in Patients with Metastatic Melanoma[J]. Clin
Cancer Res, 2021, 27(19): 5289-5298.
[17] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer[J]. N Engl
J Med, 2010, 363(5): 411-422.
[20] Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled
phaseⅢ trial of immunologic therapy with sipuleucel-T
(APC8015) in patients with metastatic, asymptomatic hormone
refractory prostate cancer[J]. J Clin Oncol, 2006, 24(19):
3089-3094.
[19] Higano CS, Schellhammer PF, Small EJ, et al. Integrated data
from 2 randomized, double-blind, placebo-controlled, phase
3 trials of active cellular immunotherapy with sipuleucel-T in
advanced prostate cancer[J]. Cancer, 2009, 115(16): 3670-3679.
[20] Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival
analysis of a phase Ⅱ randomized controlled trial of a Poxviralbased
PSA-targeted immunotherapy in metastatic castrationresistant
prostate cancer[J]. J Clin Oncol, 2010, 28(7): 1099-1105.
[21] Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors
for the Treatment of Cancer: Clinical Impact and Mechanisms of
Response and Resistance[J]. Annu Rev Pathol, 2021, 16: 223-249.
[22] Venkatachalam S, McFarland TR, Agarwal N, et al. Immune
Checkpoint Inhibitors in Prostate Cancer[J]. Cancers (Basel),
2021, 13(9): 2187.
[23] Vitkin N, Nersesian S, Siemens DR, et al. The Tumor Immune
Contexture of Prostate Cancer[J]. Front Immunol, 2019, 10: 603.
[24] Tsaur I, Brandt MP, Juengel E, et al. Immunotherapy in prostate
cancer: new horizon of hurdles and hopes[J]. World J Urol, 2021,
39(5): 1387-1403.
[25] Sena LA, Denmeade SR, Antonarakis ES. Targeting the spectrum
of immune checkpoints in prostate cancer[J]. Expert Rev Clin
Pharmacol, 2021, 14(10): 1253-1266.
[26] Handa S, Hans B, Goel S, et al. Immunotherapy in prostate cancer:
current state and future perspectives[J]. Ther Adv Urol, 2020, 12:
1756287220951404.
[27] Abdul Sater H, Marté JL, Donahue RN, et al. Neoadjuvant
PROSTVAC prior to radical prostatectomy enhances T-cell
infiltration into the tumor immune microenvironment in men with
prostate cancer[J]. J Immunother Cancer, 2020, 8(1): e000655.
[28] Subudhi SK, Siddiqui BA, Aparicio AM, et al. Combined CTLA-4
and PD-L1 blockade in patients with chemotherapy-na?ve
metastatic castration-resistant prostate cancer is associated with
increased myeloid and neutrophil immune subsets in the bone
microenvironment[J]. J Immunother Cancer, 2021, 9(10): e002919.
[29] Pachynski RK, Morishima C, Szmulewitz R, et al. IL-7 expands
lymphocyte populations and enhances immune responses to
sipuleucel-T in patients with metastatic castration-resistant
prostate cancer (mCRPC)[J]. J Immunother Cancer, 2021,9(8):
e002903.
[30] Collins JM, Redman JM, Gulley JL. Combining vaccines and
immune checkpoint inhibitors to prime, expand, and facilitate
effective tumor immunotherapy[J]. Expert Rev Vaccines, 2018,
17(8): 697-705. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
